Stem cell-based risk scoring tool could predict AML patient’s response to standard treatment – News-Medical.net
News-Medical.net |
Stem cell-based risk scoring tool could predict AML patient's response to standard treatment
News-Medical.net Leukemia researchers at Princess Margaret Cancer Centre have developed a 17-gene signature derived from leukemia stem cells that can predict at diagnosis if patients with acute myeloid leukemia (AML) will respond to standard treatment. The findings … Stem cell biomarker predicts leukemia patients' response to chemo Signature of 17 Genes Could Predict Prognosis in AML Patients Cancer vaccine prolongs remission in leukemia patients in trial |
